Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Centessa Pharmaceuticals
Thumbnail
May 09, 2022

Asset resuscitation fails to resuscitate Mereo

Mereo claims another success with a big pharma castoff, but its win in alpha 1-antitrypsin deficiency is questionable.

Thumbnail
May 05, 2022

Jazz overture rekindles hopes for orexin agonism

Article image
Vantage logo
November 02, 2021

Centessa claims a place in the antitrypsin deficiency pipeline

But investors will need more convincing; and others are more advanced, with Arrowhead and Inhibrx ones to watch.

Article image
Vantage logo
October 05, 2021

Biotech listings show signs of a slowdown

2021 is on track to beat last year’s monster haul, but the IPO window could finally be closing.

Article image
Vantage logo
September 30, 2021

Merck & Co justifies paying up for Acceleron

But with the obvious buyer, Bristol, having apparently been outbid, there might be questions over Acceleron’s takeout price.

Article image
Vantage logo
September 09, 2021

Centessa takes a step towards a new haemophila mechanism

Article image
Vantage logo
July 01, 2021

Biotech listings shows few signs of cooling

IPOs of drug developers raised $9bn in the first half of 2021, a record amount that is hard to square with talk of moderation.

Article image
Vantage logo
April 07, 2021

Biotech venture financing starts the year with a bang

With a record $7.1bn raised in the first quarter the cash available to private drug developers shows no signs of drying up.

We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

June 16, 2022

Vantage Top 10 Most Read Report

June 15, 2022

Asco 2022 eBook

View more...

Editor's Picks

Vantage logo
June 14, 2022

Roche deal fails to Repare the licensing scene

Vantage logo
June 13, 2022

EHA 2022 – Crispr still looks bloody good

Vantage logo
June 05, 2022

Asco 2022 – Enhertu asks, how low can you go?

Vantage logo
June 09, 2022

Asco 2022 movers – cell therapy wins, but it’s not the whole story

Vantage logo
May 30, 2022

Abbvie to become the biggest of pharmas in 2028

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.